Hindered by various issues recently, the pharma sector is trading at a four-year low valuation (and at par with its 10 year average). Blue chip pharma companies have been beaten down by the concerns around pricing, compliance issues and a fear of shrinking growth in the large US market. In this note, we have tried to distinguish between the truth and hype surrounding these pain points.